Price T Rowe Associates Inc. MD Trims Stock Holdings in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Price T Rowe Associates Inc. MD reduced its stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 9.4% during the 2nd quarter, Holdings Channel reports. The fund owned 38,374 shares of the company’s stock after selling 3,978 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $1,595,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of FMS. First Trust Advisors LP lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 12.5% in the first quarter. First Trust Advisors LP now owns 86,559 shares of the company’s stock valued at $3,508,000 after acquiring an additional 9,624 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 441.9% in the first quarter. JPMorgan Chase & Co. now owns 2,162 shares of the company’s stock valued at $80,000 after acquiring an additional 1,763 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 43.9% in the first quarter. Ameriprise Financial Inc. now owns 17,825 shares of the company’s stock valued at $657,000 after acquiring an additional 5,437 shares in the last quarter. Captrust Financial Advisors lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 291.3% in the first quarter. Captrust Financial Advisors now owns 4,633 shares of the company’s stock valued at $171,000 after acquiring an additional 3,449 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 17.2% in the first quarter. Schonfeld Strategic Advisors LLC now owns 10,200 shares of the company’s stock valued at $376,000 after acquiring an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 3.46% of the company’s stock.

Shares of NYSE:FMS opened at $31.10 on Thursday. The firm has a market capitalization of $18.22 billion, a PE ratio of 16.63 and a beta of 1.22. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.78. The business has a 50-day moving average of $34.46 and a two-hundred day moving average of $38.23. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $30.80 and a 12 month high of $43.33.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its quarterly earnings results on Tuesday, November 2nd. The company reported $0.55 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.55. The company had revenue of $5.24 billion during the quarter, compared to analyst estimates of $5.37 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.74% and a net margin of 5.28%. As a group, research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.96 earnings per share for the current year.

FMS has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, November 5th. Societe Generale reiterated a “hold” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, August 4th. Barclays reiterated an “equal weight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Thursday, October 21st. HSBC initiated coverage on Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday. They set a “hold” rating on the stock. Finally, Berenberg Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, November 10th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $38.33.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG & Co KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Further Reading: What does a neutral rating on stocks mean?

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS).

Institutional Ownership by Quarter for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.